Andrew Feldman, M.D., Consultant, Division of Hematopathology at Mayo Clinic, has become the first recipient of the newly established Berard–Dorfman Founders Award from the Society for Hematopathology.
The award specifically acknowledges Dr. Feldman’s extensive contributions in understanding pathophysiologic mechanisms important in lymphoma along with his record of teaching and mentorship.
About the Award
The Berard–Dorfman Founders Award was established to commemorate Drs. Costan W. Berard and Ronald F. Dorfman who co–founded the Society for Hematopathology in 1981. It is awarded to young investigators who demonstrate excellence in research.
Dr. Feldman was presented with the award on March 22 at the Annual Meeting of the United States and Canadian Academy of Pathology. The presentation at the award ceremony cited “Dr. Feldman’s relentless focus led to the identification of new genetic lesions, which provide new diagnostic tools, allow for individualized therapy, and carry a potential for a development of new targeted therapies. Dr. Feldman is a physician-scientist of proven ability and potential. He is deserving of this award as a diagnostic hematopathologist and translational scientist. He is a role model for future generations.”
About Andrew Feldman, M.D.
Dr. Feldman joined the staff of Mayo Clinic in Rochester in 2006. He is a Consultant in the Department of Pathology with joint appointments in the Divisions of Hematopathology, Experimental Pathology, and Anatomic Pathology. He holds the academic rank of Associate Professor of Laboratory Medicine and Pathology. Dr. Feldman’s research program focuses on the molecular pathogenesis of T–cell lymphomas, with the goal of translating mechanistic understanding of disease biology to laboratory tests that improve diagnostic accuracy and guide individualized therapy. He is a Damon Runyon Foundation Clinical Investigator and receives funding from the National Cancer Institute, the American Cancer Society, the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence, the Center for Individualized Medicine, and DLMP.
Dr. Feldman was also recently elected to membership in the International Lymphoma Study Group (ILSG). The ILSG was founded in 1991 by Drs. Peter Isaacson and Harald Stein and developed the Revised European-American Classification of Lymphoid Neoplasms, which led to the current World Health Organization classification of lymphomas.